<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Another important consideration during management of COVID-19 patients is drug-drug interaction in the treatment of COVID-19, especially with concomitant use of antiarrhythmics and anticoagulants. For instance, the levels of hepatically eliminated AADs including amiodarone, propafenone, flecainide, quinidine, and some novel oral anticoagulants including apixaban and rivaroxaban, which are metabolized mainly by different CP450 isoenzymes (e.g., CYP3A4, CYP2C9), can be increased by coadministration of lopinavir/ritonavir, as it inhibits CYP3A4 (
 <xref rid="bib66" ref-type="bibr">66</xref>,
 <xref rid="bib73" ref-type="bibr">73</xref>). 
 <xref rid="tbl1" ref-type="table">TableÂ 1</xref> summarizes the potential interactions of drugs used for COVID-19 therapy with cardiac drugs.
</p>
